FDA statement on amalgam
Comments are off for this post.
People with known heightened sensitivity (allergy) to mercury or other components of dental amalgam should not get amalgam fillings, according to FDA’s new directives on amalgam fillings. Inhaling mercury vapour “may be harmful in certain patients” and “uncertainties remain on the effects that long-term exposure to dental amalgam may have on the specific high-risk groups”.
FDA’s definition of “high-risk groups” include pregnant/nursing women and children under 6 years, bringing the US in-line with European legislation. But in addition they add:
• People with pre-existing neurological disease such as multiple sclerosis, Alzheimer’s disease or Parkinson’s disease
• People with impaired kidney function
• People with known heightened sensitivity (allergy) to mercury or other components of dental amalgam.
This is a major victory for all those who have campaigned for two decades to raise awareness of the toxic and hypersensitive effects of dental amalgam. FDA also mention the representatives from “underserved communities, who expressed concern about the cumulative effect of mercury vapor exposure from dental amalgam, as well as from other (dietary and environmental) sources.”
You can hear the inspiring speakers from the 2019 FDA meeting with speakers starting at 00:24:00 on their website
Congratulations to you all on your persistence and professionalism – it was an honour to be with you all last year!